On August 28, 2025 TriSalus Life Sciences Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, reported that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in September (Press release, TriSalus Life Sciences, AUG 28, 2025, View Source [SID1234655570]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Global Healthcare Conference 2025 in New York, NY
Management will participate in one-on-one meetings and participate in a fireside chat on Friday, September 5, at 9:35 a.m. ET. Click here for a link to the live webcast.

Lake Street Capital Markets 9th Annual Best Ideas Growth Conference in New York, NY
Management will participate in one-on-one meetings on Thursday, September 11.

A webcast replay of the fireside chat will be available for 90 days following the presentation in the Events section of the TriSalus Investor website at www.investors.trisaluslifesci.com.